Details of the Drug

General Information of Drug (ID: DMUIE76)

Drug Name

Acetaminophen

Synonyms

acetaminophen; 4-Acetamidophenol; Paracetamol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Acetaminofen; Panadol; Datril; p-Hydroxyacetanilide; N-Acetyl-p-aminophenol; p-Acetamidophenol; Algotropyl; Naprinol; Lonarid; 4'-Hydroxyacetanilide; Multin; Acenol; Acamol; Anelix; p-Acetaminophenol; Liquagesic; Acetagesic; Gelocatil; Servigesic; Acetalgin; Abensanil; Pyrinazine; Injectapap; Clixodyne; Valgesic; Tussapap; Finimal; Paracet; Homoolan; Febrolin; Febrilix; Febridol; Dymadon; Anaflon; Apamide; Valadol; Tralgon; Tabalgin; Lestemp; Alvedon; Abenol; Abrol; Abrolet; Acephen; Acertol; Acetaco; Acetamol; Acetavance; Acetofen; Actamin; Actimol; Afebrin; Afebryl; Aferadol; Algesidal; Algina; Algomol; Alpiny; Alpinyl; Amadil; Aminofen; Analter; Anapap; Andox; Anhiba; Antidol; Anuphen; Apacet; Apadon; Apitrelal; Arfen; Arthralgen; Asetam; Asomal; Aspac; Asplin; Atasol; Atralidon; Babikan; Bacetamol; Banesin; Benmyo; Biocetamol; Cadafen; Calapol; Calmanticold; Calonal; Calpol; Capital; Captin; Causalon; Cefalex; Cetadol; Codabrol; Codalgin; Codapane; Codicet; Codisal; Codoliprane; Cofamol; Conacetol; Cosutone; Cuponol; Curadon; Curpol; Custodial; Dafalgan; Darocet; Darvocet; Daygrip; Deminofen; Democyl; Demogripal; Desfebre; Dhamol; Dimindol; Dirox; Disprol; Dolcor; Dolefin; Dolegrippin; Dolgesic; Doliprane; Dolko; Dolofugin; Doloreduct; Dolorfug; Dolorstop; Dolotec; Dolprone; Dorocoff; Dresan; Dristancito; Duaneo; Dularin; Duorol; Duracetamol; Durapan; Dypap; Ecosetol; Elixodyne; Empracet; Enelfa; Eneril; Excipain; Exdol; Fanalgic; Farmadol; Febranine; Febrectal; Febrectol; Febrex; Febricet; Febrin; Febrinol; Fendon; Fensum; Fepanil; Fevor; Finiweh; Fluparmol; Geluprane; Genapap; Genebs; Grippostad; Gynospasmine; Hedex; Ildamol; Inalgex; Infadrops; Janupap; Kataprin; Korum; Labamol; Lekadol; Lemgrip; Lemsip; Liqiprine; Lupocet; Lyteca; Magnidol; Malgis; Malidens; Maxadol; Medocodene; Mexalen; Minafen; Minoset; Miralgin; Momentum; NEBS; Napafen; Nealgyl; NeoCitran; Neodol; Neodolito; Neopap; Neotrend; Neuridon; NilnOcen; Nina; Nobedon; Nodolex; Noral; Ofirmev; Oltyl; Oralgan; Ortensan; Oxycocet; Paceco; Pacemo; Pacemol; Pacet; Pacimol; Paedialgon; Paedol; Painex; Paldesic; Pamol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorb; Panasorbe; Panets; Panex; Panodil; Panofen; Pantalgin; Paracemol; Paracenol; Paracetamole; Paracetamolo; Paracetanol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Parakapton; Parake; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parapan; Parasedol; Parasin; Paraspen; Parcetol; Parelan; Parmol; Parogal; Paroma; Pasolind; Pediapirin; Pediatrix; Pedric; Perfalgan; Phendon; Phenipirin; Phogoglandin; Pinex; Piramin; Pirinasol; Plicet; Polmofen; Predimol; Predualito; Prodol; Prompt; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Redutemp; Reliv; Remedol; Rivalgyl; Robigesic; Rounox; RubieMol; Rubophen; Rupemol; Salzone; Sanicet; Sanicopyrine; Scanol; Scentalgyl; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Setol; Sifenol; Sinaspril; Sinedol; Sinmol; Stanback; Stopain; Sunetheton; Supofen; Suppap; TYL; Tachiprina; Tapanol; Tapar; Tazamol; Temlo; Tempanal; Tempra; Termacet; Termalgin; Termalgine; Termofren; Tiffy; Titralgan; Treuphadol; Tricoton; Tylex; Tylol; Tymol; Upsanol; Utragin; Valorin; Veralgina; Vermidon; Verpol; Vips; Viruflu; Vivimed; Volpan; Zatinol; Zolben; Aceta Elixir; Actifed Plus; Aspirin free anacin; Bayer Select; D oliprane; Dymadon Co; Fortalidon P; Gattaphen T; Gripin Bebe; Helon N; Influbene N; Jin Gang; Lonarid Mono; Lyteca Syrup; Malex N; Panadeine Co; Panale ve; Pasolind N; Spalt N; Supadol mono; Toximer P; Treupel N; Treupel mon; Ty lenol; Tylex CD; Anacin 3; A-Per; Accu-Tap; Ultracet

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1]
Arrhythmia	BC9Z	Approved	[1]
Back pain	ME84.Z	Approved	[1]
Common cold	CA00	Approved	[1]
Fever	MG26	Approved	[1]
Headache	8A80-8A84	Approved	[1]
Migraine disorder	N.A.	Approved	[1]
Pain	MG30-MG3Z	Approved	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

151.16

Logarithm of the Partition Coefficient (xlogp)

0.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 90 min [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 88% [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 5 mL/min/kg [5]
Elimination: Less than 5% is excreted in the urine as free (unconjugated) acetaminophen and at least 90% of the administered dose is excreted within 24 hours []
Half-life: The concentration or amount of drug in body reduced by one-half in 2.5 hours [3]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 330.76126 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.52% [5]
Vd: The volume of distribution (Vd) of drug is 0.9 L/kg [7]
Water Solubility: The ability of drug to dissolve in water is measured as 23.7 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cytogenetic abnormality	Not Available	PAP	OTIODT03	[8]
Hepatotoxicity	rs6852435	KIAA1712	OTZLD83K	[9]
Hepatotoxicity	rs2880961	C3orf38	OTK4O2C1	[9]
Hepatotoxicity	rs1532815	LMX1A	OTEEYD5L	[9]
Hepatotoxicity	Not Available	SLC12A3	OTAO2PG6	[8]
Hepatotoxicity	Not Available	ODC1	OTNDAGRR	[8]
Hepatotoxicity	Not Available	FOS-FOX	OTXKFLFB	[8]
Hyperglycaemia	Not Available	GPT2	OTS5VF7N	[8]
Lysosomal storage disorders	Not Available	lytD	OTYJDOLG	[8]
Renal function abnormal	Not Available	CYP11B1	OTKKL894	[8]
Renal impairment	Not Available	CYP76B1	OTKGRXC4	[8]
Respiratory, thoracic and mediastinal disorders	Not Available	MPO	OTOOXLIN	[8]
Toxic epidermal necrolysis	HLA-A*33:03	HLA-A	OTAH14LU	[10]
-----------


⏷ Show the Full List of 13 ADR Information of This Drug

Chemical Identifiers

Formula: C8H9NO2
IUPAC Name: N-(4-hydroxyphenyl)acetamide
Canonical SMILES: CC(=O)NC1=CC=C(C=C1)O
InChI: InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)
InChIKey: RZVAJINKPMORJF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 1983
ChEBI ID: CHEBI:46195
CAS Number: 103-90-2
DrugBank ID: DB00316
TTD ID: D0U5QK
VARIDT ID: DR01006
INTEDE ID: DR0037
ACDINA ID: D00009

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[11]
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN ; PGH2_HUMAN	Inhibitor	[12]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[11]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[14]
Cytochrome P450 2E1 (CYP2E1)_{Main DME}	DEVDYN7	CP2E1_HUMAN	Substrate	[15]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[14]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[16]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[17]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[18]
Glutathione S-transferase alpha-1 (GSTA1)	DE4ZHS1	GSTA1_HUMAN	Substrate	[19]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[14]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[20]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[21]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[22]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Substrate	[23]
UDP-glucuronosyltransferase 1A6 (UGT1A6)	DESD26P	UD16_HUMAN	Substrate	[24]
UDP-glucuronosyltransferase 2B15 (UGT2B15)	DENZ6B1	UDB15_HUMAN	Substrate	[25]
Cytochrome P450 102A1 (cyp102)	DE4OGUF	CPXB_BACMB	Substrate	[26]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
(3R)-3-hydroxyacyl-CoA dehydrogenase (HSD17B8)	OTX1DWEF	DHB8_HUMAN	Gene/Protein Processing	[27]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Gene/Protein Processing	[28]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2)	OT5I4Y9K	PLCB_HUMAN	Gene/Protein Processing	[29]
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5)	OTNY3VMD	PLCE_HUMAN	Gene/Protein Processing	[28]
1-acyl-sn-glycerol-3-phosphate acyltransferase gamma (AGPAT3)	OTAUR5TG	PLCC_HUMAN	Gene/Protein Processing	[30]
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 (ABHD5)	OTY829Z3	ABHD5_HUMAN	Gene/Protein Processing	[30]
1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 (PNPLA3)	OTR4990X	PLPL3_HUMAN	Gene/Protein Processing	[30]
1-phosphatidylinositol 3-phosphate 5-kinase (PIKFYVE)	OTO3HGAA	FYV1_HUMAN	Gene/Protein Processing	[31]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1)	OT9HYT7A	PLCB1_HUMAN	Gene/Protein Processing	[27]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4)	OTPA0QHW	PLCB4_HUMAN	Gene/Protein Processing	[31]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Allergic rhinitis

ICD Disease Classification

CA08.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serotonin transporter (SERT)	DTT	SLC6A4	8.76E-01	7.18E-05	6.19E-04
Multidrug resistance-associated protein 2 (ABCC2)	DTP	MRP2	6.25E-01	8.95E-02	8.58E-01
Sulfotransferase 1A1 (SULT1A1)	DME	SULT1A1	2.45E-01	1.10E-01	2.25E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	4.53E-01	4.14E-02	1.83E-01
Cytochrome P450 2E1 (CYP2E1)	DME	CYP2E1	9.45E-02	-1.86E-01	-9.83E-01
UDP-glucuronosyltransferase 2B15 (UGT2B15)	DME	UGT2B15	4.75E-01	9.00E-02	8.57E-01
Cytochrome P450 2A6 (CYP2A6)	DME	CYP2A6	8.99E-01	4.59E-03	2.19E-02
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	8.46E-01	-6.63E-03	-4.49E-02
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.57E-01	9.43E-03	1.29E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	7.84E-01	-1.03E-01	-4.48E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	2.35E-01	2.78E-02	2.09E-01
Glutathione S-transferase alpha-1 (GSTA1)	DME	GSTA1	5.78E-01	3.39E-02	1.54E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Acetaminophen

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Prilocaine	DMI7DZ2	Major	Increased risk of methemoglobinemia by the combination of Acetaminophen and Prilocaine.	Pain [MG30-MG3Z]	[32]
Flavoxate	DMKV4NL	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Flavoxate.	Pain [MG30-MG3Z]	[33]
-----------

Coadministration of a Drug Treating the Disease Different from Acetaminophen (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[32]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Thioguanine.	Acute myeloid leukaemia [2A60]	[34]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Acetaminophen caused by Arn-509 mediated induction of UGT.	Acute myeloid leukaemia [2A60]	[35]
Scopolamine	DMOM8AL	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Scopolamine.	Addictive disorder [6C50-6C5Z]	[33]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[36]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Acetaminophen caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[37]
Oxazepam	DMXNZM4	Minor	Decreased metabolism of Acetaminophen caused by Oxazepam mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[38]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Acetaminophen and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[39]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Acetaminophen caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[40]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Acetaminophen and Anisindione.	Coagulation defect [3B10]	[41]
Methohexital	DM7YMIT	Moderate	Increased metabolism of Acetaminophen caused by Methohexital mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[40]
Thiopental	DMGP8AX	Moderate	Increased metabolism of Acetaminophen caused by Thiopental mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[40]
Ethanol	DMDRQZU	Major	Increased risk of hepatotoxicity by the combination of Acetaminophen and Ethanol.	Cystitis [GC00]	[42]
Hyoscyamine	DM804UR	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Hyoscyamine.	Digestive system disease [DE2Z]	[33]
Mepenzolate	DM8YU2F	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Mepenzolate.	Digestive system disease [DE2Z]	[33]
Oxybutynine	DMJPBAX	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Oxybutynine.	Discovery agent [N.A.]	[33]
Trihexyphenidyl	DMB19L8	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Trihexyphenidyl.	Dystonic disorder [8A02]	[33]
Primidone	DM0WX6I	Moderate	Increased metabolism of Acetaminophen caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Mephenytoin	DM5UGDK	Moderate	Increased metabolism of Acetaminophen caused by Mephenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[43]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Acetaminophen caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[43]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Acetaminophen caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[43]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Acetaminophen caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Acetaminophen caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[44]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Cannabidiol.	Epileptic encephalopathy [8A62]	[35]
Solifenacin	DMG592Q	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Solifenacin.	Functional bladder disorder [GC50]	[33]
Tolterodine	DMSHPW8	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Tolterodine.	Functional bladder disorder [GC50]	[33]
Darifenacin	DMWXLYZ	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Darifenacin.	Functional bladder disorder [GC50]	[33]
Propantheline	DM2EN6G	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Propantheline.	Gastric ulcer [DA60]	[33]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Acetaminophen caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[44]
Isoniazid	DM5JVS3	Moderate	Increased metabolism of Acetaminophen caused by Isoniazid mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[45]
Rifampin	DMA8J1G	Minor	Increased risk of hepatotoxicity by the combination of Acetaminophen and Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[40]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[46]
Zidovudine	DM4KI7O	Minor	Increased risk of hepatotoxicity by the combination of Acetaminophen and Zidovudine.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[48]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Acetaminophen caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[32]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Acetaminophen and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[49]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Acetaminophen and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[50]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Acetaminophen and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[51]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Acetaminophen caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[52]
Belladonna	DM2RBWK	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Belladonna.	Infectious gastroenteritis/colitis [1A40]	[33]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Acetaminophen caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[40]
Clidinium	DMUMQZ0	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Clidinium.	Irritable bowel syndrome [DD91]	[33]
Dicyclomine	DMZSDGX	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Dicyclomine.	Irritable bowel syndrome [DD91]	[33]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Methotrexate.	Leukaemia [2A60-2B33]	[35]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Acetaminophen caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[35]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Acetaminophen caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[32]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Acetaminophen caused by PF-06463922 mediated induction of UGT.	Lung cancer [2C25]	[32]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[53]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Idelalisib.	Mature B-cell leukaemia [2A82]	[54]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Clofarabine.	Mature B-cell lymphoma [2A85]	[55]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Acetaminophen caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[56]
Propranolol	DM79NTF	Minor	Decreased metabolism of Acetaminophen caused by Propranolol.	Migraine [8A80]	[57]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Acetaminophen caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[58]
Imatinib	DM7RJXL	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Imatinib.	Myeloproliferative neoplasm [2A20]	[59]
Metoclopramide	DMFA5MY	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Metoclopramide.	Nausea/vomiting [MD90]	[32]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Acetaminophen caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[60]
Biperiden	DME78OA	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Biperiden.	Parkinsonism [8A00]	[33]
Procyclidine	DMHFJDT	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Procyclidine.	Parkinsonism [8A00]	[33]
Ranitidine	DM0GUSX	Minor	Increased risk of hepatotoxicity by the combination of Acetaminophen and Ranitidine.	Peptic ulcer [DA61]	[61]
Methylscopolamine	DM5VWOB	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Methylscopolamine.	Peptic ulcer [DA61]	[33]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Acetaminophen and Leflunomide.	Rheumatoid arthritis [FA20]	[50]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[35]
Epirubicin	DMPDW6T	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[32]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Acetaminophen caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[35]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Acetaminophen and Naltrexone.	Substance abuse [6C40]	[62]
Warfarin	DMJYCVW	Moderate	Increased risk of bleeding by the combination of Acetaminophen and Warfarin.	Supraventricular tachyarrhythmia [BC81]	[41]
Liraglutide	DM3FXPS	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Liraglutide.	Type 2 diabetes mellitus [5A11]	[63]
Atropine	DMEN6X7	Minor	Altered absorption of Acetaminophen due to GI dynamics variation caused by Atropine.	Unspecific substance harmful effect [NE6Z]	[33]
-----------


⏷ Show the Full List of 68 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acesulfame	E00341	36573	Flavoring agent
Allura red AC dye	E00338	33258	Colorant
Ascorbyl palmitate	E00581	54680660	Antioxidant
Aspartame	E00402	134601	Flavoring agent
Benzyl alcohol	E00010	244	Antimicrobial preservative; Solvent
Butylparaben	E00142	7184	Antimicrobial preservative
Calcium carbonate	E00198	10112	Binding agent; Buffering agent; Diluent; Opacifying agent
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
D&C red no. 33	E00261	19116	Colorant
DL-alpha-tocopherol	E00052	2116	Antioxidant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
FD&C yellow no. 5 free acid	E00246	16014	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Lauryl sulfate	E00189	8778	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Maltitol	E00423	493591	Binding agent; Coating agent; Diluent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Menthol	E00050	1254	Flavoring agent
methylparaben	E00149	7456	Antimicrobial preservative
Oleic acid	E00421	445639	Emulsifying agent; Penetration agent; Solubilizing agent
Potassium acetate	E00430	517044	Film/membrane-forming agent
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Propylparaben sodium	E00567	23679044	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium ethylparaben	E00568	23681179	Antimicrobial preservative
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium methylparaben	E00543	23663626	Antimicrobial preservative
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Vanillin	E00049	1183	Flavoring agent
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dextrose monohydrate	E00538	22814120	Binding agent; Diluent; Flavoring agent; Tonicity agent
Edetate calcium disodium	E00487	6093170	Complexing agent
Edetate disodium	E00186	8759	Complexing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Fructose	E00447	2723872	Flavoring agent
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Hexasodium hexametaphosphate	E00316	24968	Other agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA	E00607	135423095	Colorant
Magnesium stearate	E00208	11177	lubricant
Medium-chain triglyceride	E00640	Not Available	Emollient; Lubricant; Surfactant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 2000	E00649	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 300	E00651	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Potassium sorbate	E00566	23676745	Antimicrobial preservative
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Sodium metabisulfite	E00444	656671	Antimicrobial preservative; Antioxidant
Sodium propionate	E00445	2723816	Antimicrobial preservative
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 83 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Acetaminophen 500 mg tablet	500 mg	Oral Tablet	Oral
Acetaminophen 160 mg tablet	160 mg	Disintegrating Oral Tablet	Oral
Acetaminophen 160 mg tablet	160 mg	Chewable Tablet	Oral
Acetaminophen 325 mg tablet	325 mg	Disintegrating Oral Tablet	Oral
Acetaminophen 650 mg tablet	650 mg	8 HR Extended Release Tablet	Oral
Acetaminophen 650 mg tablet	650 mg	Extended Release Oral Tablet	Oral
Acetaminophen 80 mg tablet	80 mg	Disintegrating Oral Tablet	Oral
Acetaminophen 80 mg tablet	80 mg	Chewable Tablet	Oral
Acetaminophen 500 mg capsule	500 mg	Oral Capsule	Oral
Acetaminophen 80 mg tablet	80 mg	Oral Tablet	Oral
Acetaminophen 650 mg tablet	650 mg	8 HR Extended Release Oral Tablet	Oral
Acetaminophen 325 mg capsule	325 mg	Oral Capsule	Oral
Acetaminophen 325 mg tablet	325 mg	Oral Tablet	Oral
Acetaminophen 650 mg tablet	650 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Acetaminophen FDA Label
2	The Diversion of Ultram, Ultracet, and generic tramadol HCL. J Addict Dis. 2006;25(2):53-8.
3	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26. doi: 10.1097/FPC.0000000000000150.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Bannwarth B, Pehourcq F: [Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues]. Drugs. 2003;63 Spec No 2:5-13.
8	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9	Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study. Toxicol Sci. 2011 Mar;120(1):33-41. doi: 10.1093/toxsci/kfq375. Epub 2010 Dec 22.
10	A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011 Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4.
11	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
12	Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
13	Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
16	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
17	Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
18	Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
19	Retinoid X receptor alpha regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol. 2005 Dec;68(6):1590-6.
20	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
21	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
22	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
23	Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
24	UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 Sep;39(9):1650-7.
25	Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos. 2011 Apr;39(4):644-52.
26	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
27	Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
28	Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
29	Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
30	Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
31	Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
32	Cerner Multum, Inc. "Australian Product Information.".
33	Clark JM, Seager SJ "Gastric emptying following premedication with glycopyrrolate or atropine." Br J Anaesth 55 (1983): 1195-9. [PMID: 6652009]
34	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
35	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
37	Douidar SM, Ahmed AE "A novel mechanism for the enhancement of acetaminophen hepatotoxicity by phenobarbital." J Pharmacol Exp Ther 240 (1987): 578-83. [PMID: 3806412]
38	Dybing E "Inhibition of acetaminophen glucuronidation by oxazepam." Biochem Pharmacol 25 (1976): 1421-5. [PMID: 938564]
39	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
40	Bock KW, Wiltfang J, Blume R, Ullrich D, Bircher J "Paracetamol as a test drug to determine glucuronide formation in man: effects of inducers and of smoking." Eur J Clin Pharmacol 31 (1987): 677-83. [PMID: 3556375]
41	Antlitz AM, Mead JA Jr, Tolentino MA "Potentiation of oral anticoagulant therapy by acetaminophen." Curr Ther Res Clin Exp 10 (1968): 501-7. [PMID: 4971464]
42	Bonkovsky HL "Acetaminophen hepatotoxicity, fasting, and ethanol." JAMA 274 (1995): 301. [PMID: 7609254]
43	Bivins BA, Rapp RP, Griffen WO Jr, Blouin R, Bustrack J "Dopamine-phenytoin interaction. A cause of hypotension in the critically ill." Arch Surg 113 (1978): 245-9. [PMID: 637689]
44	Miners JO, Attwood J, Birkett DJ "Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways." Clin Pharmacol Ther 35 (1984): 480-6. [PMID: 6705446]
45	Crippin JS "Acetaminophen hepatotoxicity: potentiation by isoniazid." Am J Gastroenterol 88 (1993): 590-2. [PMID: 8470644]
46	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
47	Ameer B "Acetaminophen hepatotoxicity augmented by zidovudine." Am J Med 95 (1993): 342. [PMID: 8368234]
48	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
49	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
50	Canadian Pharmacists Association.
51	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
52	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
53	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
54	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
55	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
56	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
57	Baraka OZ, Truman CA, Ford JM, Roberts CJ. The effect of propranolol on paracetamol metabolism in man.?Br J Clin Pharmacol. 1990;29(2):261-264. [PMID: 2306420]
58	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
59	Lin NU, Sarantopoulos S, Stone JR, et al. "Fatal hepatic necrosis following imatinib mesylate therapy." Blood 102 (2003): 3455-6. [PMID: 14568907]
60	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
61	Jack D, Thomas M, Skidmore IF "Ranitidine and paracetamol metabolism." Lancet 2 (1985): 1067. [PMID: 2865542]
62	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
63	Product Information. Victoza (liraglutide). Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.